



EUROPEAN MEDICINES AGENCY
SCIENCE MEDICINES HEALTH

EMA/85287/2023

European Medicines Agency decision P/0074/2023

of 10 March 2023

on the agreement of a paediatric investigation plan and on the granting of a deferral and on the granting of a waiver for (S)-2-hydroxy-6-((4-(2-(2-hydroxyethyl) nicotinoyl) morpholin-3-yl) methoxy) benzaldehyde (GBT021601) (EMEA-003241-PIP01-22) in accordance with Regulation (EC) No 1901/2006 of the European Parliament and of the Council

Disclaimer

This decision does not constitute entitlement to the rewards and incentives referred to in Title V of Regulation (EC) No 1901/2006.

Only the English text is authentic.



European Medicines Agency decision

P/0074/2023

of 10 March 2023

on the agreement of a paediatric investigation plan and on the granting of a deferral and on the granting of a waiver for (S)-2-hydroxy-6-((4-(2-(2-hydroxyethyl) nicotinoyl) morpholin-3-yl) methoxy) benzaldehyde (GBT021601) (EMEA-003241-PIP01-22) in accordance with Regulation (EC) No 1901/2006 of the European Parliament and of the Council

The European Medicines Agency,

Having regard to the Treaty on the Functioning of the European Union,

Having regard to Regulation (EC) No 1901/2006 of the European Parliament and of the Council of 12 December 2006 on medicinal products for paediatric use and amending Regulation (EEC) No. 1768/92, Directive 2001/20/EC, Directive 2001/83/EC and Regulation (EC) No 726/2004¹,

Having regard to Regulation (EC) No 726/2004 of the European Parliament and of the Council of 31 March 2004 laying down Union procedures for the authorisation and supervision of medicinal products for human use and establishing a European Medicines Agency²,

Having regard to the application submitted by Global Blood Therapeutics Netherlands B.V. on 22 April 2022 under Article 16(1) of Regulation (EC) No 1901/2006 also requesting a deferral under Article 20 of said Regulation and a waiver under Article 13 of said Regulation,

Having regard to the opinion of the Paediatric Committee of the European Medicines Agency, issued on 20 January 2023, in accordance with Article 17 of Regulation (EC) No 1901/2006 and Article 21 of said Regulation and Article 13 of said Regulation,

Having regard to Article 25 of Regulation (EC) No 1901/2006,

Whereas:

- (1) The Paediatric Committee of the European Medicines Agency has given an opinion on the agreement of a paediatric investigation plan and on the granting of a deferral and on the granting of a waiver.
- (2) It is therefore appropriate to adopt a decision agreeing a paediatric investigation plan.
- (3) It is therefore appropriate to adopt a decision granting a deferral.
- (4) It is therefore appropriate to adopt a decision granting a waiver.

¹ OJ L 378, 27.12.2006, p.1, as amended.

² OJ L 136, 30.4.2004, p. 1, as amended.

Has adopted this decision:

Article 1

A paediatric investigation plan for (S)-2-hydroxy-6-((4-(2-(2-hydroxyethyl) nicotinoyl) morpholin-3-yl) methoxy) benzaldehyde (GBT021601), tablet, age-appropriate oral solid dosage form, oral use, the details of which are set out in the opinion of the Paediatric Committee of the European Medicines Agency annexed hereto, together with its appendices, is hereby agreed.

Article 2

A deferral for (S)-2-hydroxy-6-((4-(2-(2-hydroxyethyl) nicotinoyl) morpholin-3-yl) methoxy) benzaldehyde (GBT021601), tablet, age-appropriate oral solid dosage form, oral use, the details of which are set out in the opinion of the Paediatric Committee of the European Medicines Agency annexed hereto, together with its appendices, is hereby granted.

Article 3

A waiver for (S)-2-hydroxy-6-((4-(2-(2-hydroxyethyl) nicotinoyl) morpholin-3-yl) methoxy) benzaldehyde (GBT021601), tablet, age-appropriate oral solid dosage form, oral use, the details of which are set out in the opinion of the Paediatric Committee of the European Medicines Agency annexed hereto, together with its appendices, is hereby granted.

Article 4

This decision is addressed to Global Blood Therapeutics Netherlands B.V., Strawinskylaan 3051, 1077ZX – Amsterdam, Netherlands.



EUROPEAN MEDICINES AGENCY
SCIENCE MEDICINES HEALTH

EMA/PDCO/870597/2022 Corr¹
Amsterdam, 20 January 2023

Opinion of the Paediatric Committee on the agreement of a Paediatric Investigation Plan and a deferral and a waiver

EMA-003241-PIP01-22

Scope of the application

Active substance(s):

(S)-2-hydroxy-6-((4-(2-(2-hydroxyethyl) nicotinoyl) morpholin-3-yl) methoxy) benzaldehyde (GBT021601)

Invented name and authorisation status:

See Annex II

Condition(s):

Treatment of sickle cell disease

Pharmaceutical form(s):

Tablet

Age-appropriate oral solid dosage form

Route(s) of administration:

Oral use

Name/corporate name of the PIP applicant:

Global Blood Therapeutics Netherlands B.V.

Basis for opinion

Pursuant to Article 16(1) of Regulation (EC) No 1901/2006 as amended, Global Blood Therapeutics Netherlands B.V. submitted for agreement to the European Medicines Agency on 22 April 2022 an application for a paediatric investigation plan for the above mentioned medicinal product and a deferral under Article 20 of said Regulation and a waiver under Article 13 of said Regulation.

The procedure started on 23 May 2022.

¹ 7 March 2023



Supplementary information was provided by the applicant on 14 October 2022. The applicant proposed modifications to the paediatric investigation plan.

Opinion

1. The Paediatric Committee, having assessed the proposed paediatric investigation plan in accordance with Article 17 of Regulation (EC) No 1901/2006 as amended, recommends as set out in the appended summary report:

- to agree the paediatric investigation plan in accordance with Article 17(1) of said Regulation;
- to grant a deferral in accordance with Article 21 of said Regulation;
- to grant a waiver for one or more subsets of the paediatric population in accordance with Article 13 of said Regulation and concluded in accordance with Article 11(1)(c) of said Regulation, on the grounds that the specific medicinal product does not represent a significant therapeutic benefit over existing treatments for paediatric patients.

The Paediatric Committee member of Norway agrees with the above-mentioned recommendation of the Paediatric Committee.

2. The measures and timelines of the agreed paediatric investigation plan and the subset(s) of the paediatric population and condition(s) covered by the waiver are set out in the Annex I.

This opinion is forwarded to the applicant and the Executive Director of the European Medicines Agency, together with its annexes and appendix.

Annex I

The subset(s) of the paediatric population and condition(s) covered by the waiver and the measures and timelines of the agreed paediatric investigation plan (PIP)

1. Waiver

1.1. Condition:

Treatment of sickle cell disease

The waiver applies to:

- the paediatric population from birth to less than 6 months of age;
- tablet, age-appropriate oral solid dosage form, oral use;
- on the grounds that clinical studies with the specific medicinal product cannot be expected to be of significant therapeutic benefit to or fulfil a therapeutic need of the specified paediatric subset(s).

2. Paediatric investigation plan

2.1. Condition:

Treatment of sickle cell disease

2.1.1. Indication(s) targeted by the PIP

Treatment of sickle cell disease

2.1.2. Subset(s) of the paediatric population concerned by the paediatric development

From 6 months to less than 18 years of age

2.1.3. Pharmaceutical form(s)

Tablet

Age-appropriate oral solid dosage form

2.1.4. Measures

Area	Description
Quality-related studies	Study 1 Development of age-appropriate oral solid dosage form
Non-clinical studies	Not applicable
Clinical studies	Study 2 (GBT021601-021 Part B) Double-blind, randomised, placebo-controlled study to evaluate safety and efficacy of GBT021601 in adolescents from 12 years to less than 18 years of age (and adults) with sickle cell disease. Study 3 (GBT021601-021 Part C) Open-label, uncontrolled study to evaluate pharmacokinetics and safety of GBT021601 in children and adolescents from 6 months to

	less than 18 years of age with sickle cell disease.
Modelling and simulation studies	Study 4 Modelling and simulation study to support dose finding in children from 12 years to less than 18 years of age with sickle cell disease. Study 5 Modelling and simulation study to support dose finding in children from 6 months to less than 12 years of age with sickle cell disease.
Other studies	Not applicable
Extrapolation plan	Studies 2, 3, 4 and 5 are part of the extrapolation plan of efficacy data from adult and adolescents to the paediatric population from 6 months to less than 12 years of age with sickle cell disease.

3. Follow-up, completion and deferral of PIP

Concerns on potential long term safety/efficacy issues in relation to paediatric use:	No
Date of completion of the paediatric investigation plan:	By June 2028
Deferral for one or more measures contained in the paediatric investigation plan:	Yes

Annex II

Information about the authorised medicinal product

Information provided by the applicant:

The product is not authorised anywhere in the European Community.